Matthew White
Director Financiero/CFO en APIAM ANIMAL HEALTH LIMITED .
Fortuna: 37 926 $ al 30/04/2024
Perfil
Matthew White is currently the Chief Financial Officer at Apiam Animal Health Ltd.
since 2015.
Prior to this, he worked as a Finance Director at Merck Sharp & Dohme (Australia) Pty Ltd.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
APIAM ANIMAL HEALTH LTD.
0.08% | 30/06/2023 | 146 017 ( 0.08% ) | 37 926 $ | 30/04/2024 |
Cargos activos de Matthew White
| Empresas | Cargo | Inicio |
|---|---|---|
| APIAM ANIMAL HEALTH LIMITED | Director Financiero/CFO | 01/08/2015 |
Antiguos cargos conocidos de Matthew White.
| Empresas | Cargo | Fin |
|---|---|---|
Merck Sharp & Dohme (Australia) Pty Ltd.
 Merck Sharp & Dohme (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme (Australia) Pty Ltd. is an Australian research-intensive biopharmaceutical company committed to saving and improving lives. The private company is based in North Ryde, Australia and is dedicated to following the science to tackle some of the world's greatest health threats. MSD Australia has a long legacy of research in infectious disease and has been mobilizing its scientific expertise and experience to develop an effective response to the COVID-19 pandemic since it was first recognized. | Director Financiero/CFO | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| APIAM ANIMAL HEALTH LIMITED | Distribution Services |
| Empresas privadas | 1 |
|---|---|
Merck Sharp & Dohme (Australia) Pty Ltd.
Merck Sharp & Dohme (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Sharp & Dohme (Australia) Pty Ltd. is an Australian research-intensive biopharmaceutical company committed to saving and improving lives. The private company is based in North Ryde, Australia and is dedicated to following the science to tackle some of the world's greatest health threats. MSD Australia has a long legacy of research in infectious disease and has been mobilizing its scientific expertise and experience to develop an effective response to the COVID-19 pandemic since it was first recognized. | Health Technology |
- Bolsa de valores
- Insiders
- Matthew White
